Kenvue Faces FDA Petition to Remove Key Benadryl Ingredient (1)

Kenvue Inc. is dealing with another challenge to a top-selling product as it attempts to close its $40 billion acquisition by Kimberly-Clark Corp.

US President Donald Trump linked the use of Kenvue’s Tylenol to autism in September. More recently three doctors filed a petition with the Food and Drug Administration that requested the agency remove the active ingredient — diphenhydramine — in over-the-counter cold, cough and allergy medications such as Kenvue’s Benadryl because there are more effective products with fewer side effects.

“The adverse reactions to diphenhydramine hydrochloride occur with recommended doses and higher than recommended doses,” said the petition ...